Clinical Report: Neoadjuvant Radiotherapy with Camrelizumab for ESCC

Overview

This phase II trial demonstrates that neoadjuvant camrelizumab combined with radiotherapy achieves high rates of major pathologic response and R0 resection in patients with locally advanced esophageal squamous cell carcinoma, while exhibiting low rates of high-grade toxicity. These findings suggest a viable chemotherapy-sparing strategy for patients unable to tolerate standard chemotherapy.

Background

Esophageal cancer, particularly esophageal squamous cell carcinoma (ESCC), poses significant treatment challenges due to its prevalence and associated morbidity. Standard treatment typically involves neoadjuvant chemoradiotherapy, which, while effective, often leads to severe toxicity. There is a pressing need for alternative strategies that enhance treatment efficacy while minimizing adverse effects, especially for vulnerable patient populations.

Data Highlights

No numerical data available in the source material.

Key Findings

• Neoadjuvant camrelizumab plus radiotherapy resulted in high rates of major pathologic response.
• The trial reported low rates of high-grade toxicity and generally mild postoperative complications.
• This approach may serve as a chemotherapy-sparing strategy for patients ineligible for standard chemotherapy.
• Conventional chemoradiotherapy is associated with significant toxicity, highlighting the need for alternative treatment options.
• Camrelizumab enhances antitumor immunity by blocking PD-1/PD-L1 interactions.

Clinical Implications

The findings from this trial indicate that neoadjuvant camrelizumab combined with radiotherapy may be a safer alternative for patients with locally advanced ESCC who cannot tolerate chemotherapy. This strategy could reshape treatment protocols and improve outcomes for a subset of patients.

Conclusion

Reiterate the need for further studies and specify what aspects should be investigated.

References

1. BJS (British Journal of Surgery), 2023 -- Evolving Approaches to Multimodal Therapy for Locally Advanced Oesophageal and Junctional Adenocarcinoma
2. The ASCO Post, 2015 -- Clinical Trials Actively Recruiting Patients With Esophageal Cancer
3. Comparison of Neoadjuvant Chemoradiotherapy Regimens Using Cisplatin/5-Fluorouracil or Carboplatin/Paclitaxel, 2023 -- Analysis of Postoperative Outcomes, Toxicity, and Pathological Response
4. ESMO Clinical Practice Guideline, 2025 -- Interim update on the treatment of locally advanced oesophageal and oesophagogastric junction adenocarcinoma
5. Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma, 2024 -- the randomized phase 3 ESCORT-NEO/NCCES01 trial
6. The ASCO Post — Neoadjuvant Chemotherapy Without Routine Radiotherapy Shows Promise in Patients With Locally Advanced Rectal Cancer
7. Neoadjuvant immunochemoradiotherapy with nivolumab, paclitaxel, and cisplatin followed by esophagectomy for locally advanced esophageal squamous cell carcinoma
8. ESMO Clinical Practice Guideline interim update on the treatment of locally advanced oesophageal and oesophagogastric junction adenocarcinoma and metastatic squamous-cell carcinoma - PMC
9. Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO/NCCES01 trial | Nature Medicine